Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775842 | 0.92 | PYGL (0.41) | HDAC8TRPV1MEN1KMT2AALDH1A1 | |
| SCHEMBL3779106 | 0.92 | ANO1 (0.37) | HDAC8TRPV1MEN1KMT2AERCC1 | |
| SCHEMBL3787305 | 0.87 | PDK1 (0.40) | HDAC8CYP3A4GAAMEN1KMT2A | |
| SCHEMBL3785370 | 0.85 | MDM2 (0.42) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL3778904 | 0.84 | MAPT (0.43) | GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL3784633 | 0.79 | GAA (0.42) | GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL3781591 | 0.77 | ALDH1A1 (0.48) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2577121 | 0.77 | LNPEP (0.39) | TRPV1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL3784324 | 0.76 | MEN1 (0.53) | TRPV1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL28322156 | 0.74 | HDAC8 (0.47) | HDAC8CYP3A4CYP2C9GAAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | HDAC8 455/4885TRPV1 1020/4885CYP3A4 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.